Zepei Feng1, Jinwei Zhang2, Weilong Tan3, Chunhui Wang3, Qiong Chen3, Chao Shen1, Haozhi Fan4, Yun Zhang1, Peng Huang1, Ming Yue5. 1. Department of Epidemiology and Biostatistics, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China. 2. Department of Anesthesiology, Affiliated Drum Tower Hospital of Medical College of Nanjing University, Nanjing, China. 3. Institute of Epidemiology and Microbiology, Eastern Theater Command Centers for Disease Prevention and Control, Nanjing, China. 4. Department of Information, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 5. Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract
Background: With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to negative recipients. Methods: Multiple databases were searched for a systematic and comprehensive up to March 2022. The primary outcomes included the percentage of sustained virological response at week 12 after the end of treatment (SVR12), adverse events (AEs; any grade), and severe adverse events (SAEs) as the endpoints. Publication bias was examined by using the funnel plots and Egger's test. Results: In total, 16 studies with 454 subjects were included in the study and the pooled estimate of SVR12, AEs, and SAEs rates were 100.0% (95% CI: 99.2-100.0), 1.9%(95%CI: 0.0-4.9), and 0.0% (95%CI: 0.0-1.5). Subgroup analysis showed that pooled SVR12 rates were 100.0% (95%CI: 99.6-100.0) for genotype (GT)1a and 96.3% (95%CI: 83.3-100.0) for GT2; 100.0% (95%CI: 98.9-100.0) for DAAs treatments; and 100.0% (95%CI: 98.2-100.0) for prophylaxis subgroup. Egger's tests showed that no publication bias was found in this study. Conclusion: This comprehensive analysis showed the high efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to HCV-negative recipients. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=246541.
Background: With the development of direct-acting antiviral agents (DAAs), the research on kidney transplantation from Hepatitis C virus (HCV)-viremic donors to HCV-negative recipients has grown. The objective of this comprehensive analysis was to evaluate the efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to negative recipients. Methods: Multiple databases were searched for a systematic and comprehensive up to March 2022. The primary outcomes included the percentage of sustained virological response at week 12 after the end of treatment (SVR12), adverse events (AEs; any grade), and severe adverse events (SAEs) as the endpoints. Publication bias was examined by using the funnel plots and Egger's test. Results: In total, 16 studies with 454 subjects were included in the study and the pooled estimate of SVR12, AEs, and SAEs rates were 100.0% (95% CI: 99.2-100.0), 1.9%(95%CI: 0.0-4.9), and 0.0% (95%CI: 0.0-1.5). Subgroup analysis showed that pooled SVR12 rates were 100.0% (95%CI: 99.6-100.0) for genotype (GT)1a and 96.3% (95%CI: 83.3-100.0) for GT2; 100.0% (95%CI: 98.9-100.0) for DAAs treatments; and 100.0% (95%CI: 98.2-100.0) for prophylaxis subgroup. Egger's tests showed that no publication bias was found in this study. Conclusion: This comprehensive analysis showed the high efficacy and safety of DAAs in kidney transplantation from HCV-viremic donors to HCV-negative recipients. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=246541.
Authors: James R Burton; Norah A Terrault; David S Goldberg; Roy D Bloom; Richard Gilroy; Julie K Heimbach; Robert S Brown; Gregory T Everson; Erin Rubin; Russ Wiesner; Elizabeth A Pomfret Journal: Transplantation Date: 2020-03 Impact factor: 4.939
Authors: Mary G Bowring; Lauren M Kucirka; Allan B Massie; Tanveen Ishaque; Sunjae Bae; Ashton A Shaffer; Jacqueline Garonzik Wang; Mark Sulkowski; Niraj Desai; Dorry L Segev; Christine M Durand Journal: Transplantation Date: 2018-12 Impact factor: 4.939
Authors: Mary G Bowring; Courtenay M Holscher; Sheng Zhou; Allan B Massie; Jacqueline Garonzik-Wang; Lauren M Kucirka; Sommer E Gentry; Dorry L Segev Journal: Am J Transplant Date: 2017-12-05 Impact factor: 8.086
Authors: Nikhil Kapila; K V Narayanan Menon; Kawtar Al-Khalloufi; Jason M Vanatta; Carla Murgas; Diego Reino; Samer Ebaid; Joshua J Shaw; Neerja Agrawal; Salwa Rhazouani; Viviana Navas; Cedric Sheffield; Asad Ur Rahman; Michael Castillo; Christina C Lindenmeyer; Charles Miller; Cristiano Quintini; Xaralambos B Zervos Journal: Hepatology Date: 2020-04-15 Impact factor: 17.425
Authors: Meghan E Sise; David S Goldberg; Jens J Kort; Douglas E Schaubel; Rita R Alloway; Christine M Durand; Robert J Fontana; Robert S Brown; John J Friedewald; Stacey Prenner; J Richard Landis; Melissa Fernando; Caitlin C Phillips; E Steve Woodle; Adele Rike-Shields; Kenneth E Sherman; Nahel Elias; Winfred W Williams; Jenna L Gustafson; Niraj M Desai; Brittany Barnaba; Silas P Norman; Mona Doshi; Samuel T Sultan; Meredith J Aull; Josh Levitsky; Dianne S Belshe; Raymond T Chung; Peter P Reese Journal: J Am Soc Nephrol Date: 2020-08-25 Impact factor: 10.121